Improved estrogen receptor assessment by PET using the novel radiotracer 18F-4FMFES in estrogen receptor-positive breast cancer patients: An ongoing phase II clinical trial
The Journal of Nuclear Medicine Feb 08, 2018
Paquette M, et al. - Researchers undertook a comparative scrutiny of the PET imaging diagnostic potential of radiotracer 4-fluoro-11β-methoxy-16α-18F-fluoroestradiol (18F-4FMFES) with that of 16α-18F-fluoroestradiol (18F-FES) in estrogen receptor-positive (ER+) breast cancer patients. When compared to 18F-FES PET, 18F-4FMFES PET displayed a lower nonspecific signal and better tumor contrast. This, in turn, led to improved diagnostic confidence and lower false-negative diagnoses.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
